FLOW (trial)
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
What is FLOW (trial)?
The first GLP-1 trial built around the kidney rather than the waistline.
Semaglutide 1 mg went up against placebo across 3,533 participants whose diabetes had already reached their kidneys (Perkovic 2024 NEJM, PMID 38785209). The kidney composite fell 24%, HR 0.76, and the study was halted early once the benefit was unmistakable. That is what drove the January 2025 Ozempic label expansion.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where FLOW (trial) comes up on this site
On GLP Watchdog, FLOW comes up in 1 research article and 1 tool.
Research that discusses it
Tools that use it
Other terms under Major trials
Where the evidence lives
- FLOW trial deep-dive
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers